Impact of Interleukin-6 in hematological malignancies

Transfusion Medicine and Hemotherapy

Volumn 40, Issue 5, 2013, Pages 336-343

  Burger, Renate ^a  

^a Division of Stem Cell Transplantation and Immunotherapy   (Germany)

Author keywords

gp130; Interleukin 6; Leukemia; Lymphoma; Multiple myeloma

Indexed keywords

ELSILIMOMAB; FE 999301; INC 424; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; RUXOLITINIB; SARILUMAB; SILTUXIMAB; SIRUKUMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CORTICOSTEROID; DEXAMETHASONE; IMMUNOTOXIN; JANUS KINASE INHIBITOR; LENALIDOMIDE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; DRUG EFFICACY; GENE CONTROL; HEMATOLOGIC MALIGNANCY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC INFLAMMATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR BIOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION LYMPHOMA; PROTEIN BLOOD LEVEL; SERUM; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH;

EID: 84886605654     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000354194     Document Type: Review

References (70)

1. Kishimoto T: IL-6: from its discovery to clinical applications. Int Immunol 2010;22: 347-352.
2. Yasukawa K, Hirano T, Watanabe Y, Muratani K, Matsuda T, Nakai S, Kishimoto T: Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 1987;6: 2939-2945.
3. Hong DS, Angelo LS, Kurzrock R: Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007;110: 1911-1928.
4. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M: IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012;122: 143-159.
5. Kishimoto T, Akira S, Narazaki M, Taga T: Interleukin-6 family of cytokines and gp130. Blood 1995;86: 1243-1254.
6. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374: 1-20.
7. Rose-John S, Scheller J, Elson G, Jones SA: Interleukin-6 biology is coordinated by membranebound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80: 227-236.
8. Jones SA, Scheller J, Rose-John S: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011;121: 3375-3383.
9. Scheller J, Chalaris A, Schmidt-Arras D, Rose- John S: The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813: 878-888.
10. Fasnacht N, Muller W: Conditional gp130 deficient mouse mutants. Semin Cell Dev Biol 2008;19: 379- 384.
11. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G: Impaired immune and acutephase responses in interleukin-6-deficient mice. Nature 1994;368: 339-342.
12. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S: Interleukin 6 is essential for in vivo development of b lineage neoplasms. J Exp Med 1995;182: 243-248.
13. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, Fujiwara H, Hirata M, Yamagami T, Nakahata T, Hirabayashi T, Yoneda Y, Tanaka K, Wang WZ, Mori C, Shiota K, Yoshida N, Kishimoto T: Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A 1996;93: 407-411.
14. Neipel F, Albrecht JC, Ensser A, Huang YQ, Li JJ, Friedman-Kien AE, Fleckenstein B: Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 1997;71: 839-842.
15. Sakakibara S, Tosato G: Viral interleukin-6: Role in Kaposi's sarcoma-associated herpesvirus: associated malignancies. J Interferon Cytokine Res 2011; 31: 791-801.
16. Hideshima T, Chauhan D, Teoh G, Raje N, Treon SP, Tai YT, Shima Y, Anderson KC: Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res 2000;6: 1180-1189.
17. Suthaus J, Adam N, Grotzinger J, Scheller J, Rose- John S: Viral interleukin-6: structure, pathophysiology and strategies of neutralization. Eur J Cell Biol 2011;90: 495-504.
18. Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, Gramatzki M: Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998;91: 1858-1863.
19. Mullberg J, Geib T, Jostock T, Hoischen SH, Vollmer P, Voltz N, Heinz D, Galle PR, Klouche M, Rose-John S: IL-6 receptor independent stimulation of human gp130 by viral IL-6. J Immunol 2000;164: 4672-4677.
20. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T: Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A 1992;89: 232-235.
21. Rutsch S, Neppalli VT, Shin DM, DuBois W, Morse HC 3rd, Goldschmidt H, Janz S: IL-6 and myc collaborate in plasma cell tumor formation in mice. Blood 2010;115: 1746-1754.
22. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW: Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990;86: 592-599.
23. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, et al.: Pathogenic significance of interleukin- 6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74: 1360-1367.
24. Burger R, Wendler J, Antoni K, Helm G, Kalden JR, Gramatzki M: Interleukin-6 production in Bcell neoplasias and Castleman's disease: evidence for an additional paracrine loop. Ann Hematol 1994;69: 25-31.
25. Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, Shaughnessy JD Jr, Hall B, Reddy M, Hoering A, Hansen E, van Rhee F: Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One 2013;8:e54610.
26. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T: Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106: 2627-2632.
27. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, Van Rhee F: A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease. Clin Cancer Res 2013;19: 3659-3670.
28. Klein B, Zhang XG, Lu ZY, Bataille R: Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863-872.
29. Anderson KC, Carrasco RD: Pathogenesis of myeloma. Annu Rev Pathol Mech Dis 2011;6: 249-274.
30. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA: Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73: 1915-1924.
31. Tanabe O, Kawano M, Tanaka H, Iwato K, Asaoku H, Ishikawa H, Nobuyoshi M, Hirano T, Kishimoto T, Kuramoto A: BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. Am J Hematol 1989;31: 258-262.
32. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, et al.: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332: 83-85.
33. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myelomacell growth and differentiation by interleukin-6. Blood 1989;73: 517-526.
34. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC: Adhesion of human myeloma- derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712-3720.
35. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10: 105-115.
36. Puthier D, Derenne S, Barille S, Moreau P, Harousseau JL, Bataille R, Amiot M: Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol 1999;107: 392-395.
37. Hideshima T, Nakamura N, Chauhan D, Anderson KC: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20: 5991-6000.
38. Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, Baum W, Duerr B, Hocke GM, Steininger H, Gebhart E, Gramatzki M: Gp130 and ras mediated signaling in human plasma cell line INA- 6: a cytokine-regulated tumor model for plasmacytoma. Hematol J 2001;2: 42-53.
39. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994;83: 3654-3663.
40. Chiron D, Maiga S, Surget S, Descamps G, Gomez- Bougie P, Traore S, Robillard N, Moreau P, Le Gouill S, Bataille R, Amiot M, Pellat-Deceunynck C: Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer J 2013;3:e120.
41. Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD Jr: An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 2012;119: 503-512.
42. Asou H, Said JW, Yang R, Munker R, Park DJ, Kamada N, Koeffler HP: Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus- associated primary effusion lymphoma cells. Blood 1998;91: 2475-2481.
43. Foussat A, Wijdenes J, Bouchet L, Gaidano G, Neipel F, Balabanian K, Galanaud P, Couderc J, Emilie D: Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8- infected malignant B lymphocytes. Eur Cytokine Netw 1999;10: 501-508.
44. Trikha M, Corringham R, Klein B, Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9: 4653-4665.
45. Emilie D, Coumbaras J, Raphael M, Devergne O, Delecluse HJ, Gisselbrecht C, Michiels JF, Van Damme J, Taga T, Kishimoto T, et al.: Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood 1992;80: 498-504.
46. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC, Blay JY: Interleukin (IL)-10 and IL-6 are produced in vivo by non- Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996;56: 5499-5505.
47. Durandy A, Emilie D, Peuchmaur M, Forveille M, Clement C, Wijdenes J, Fischer A: Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice. J Immunol 1994;152: 5361-5367.
48. Mauray S, Fuzzati-Armentero MT, Trouillet P, Ruegg M, Nicoloso G, Hart M, Aarden L, Schapira M, Duchosal MA: Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. Eur J Immunol 2000;30: 2065-2073.
49. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q: Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 2012;120: 3783-3792.
50. Hoang T, Haman A, Goncalves O, Wong GG, Clark SC: Interleukin-6 enhances growth factordependent proliferation of the blast cells of acute myeloblastic leukemia. Blood 1988;72: 823-826.
51. Sugiyama H, Inoue K, Ogawa H, Yamagami T, Soma T, Miyake S, Hirata M, Kishimoto T: The expression of IL-6 and its related genes in acute leukemia. Leuk Lymphoma 1996;21: 49-52.
52. Xie P, Chan FS, Ip NY, Leung MF: IL-6 enhanced the retinoic acid-induced differentiation of human acute promyelocytic leukemia cells. Cancer Lett 2000;148: 207-213.
53. Aoki Y, Yarchoan R, Wyvill K, Okamoto S, Little RF, Tosato G: Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood 2001;97: 2173-2176.
54. Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, Janz S, Scheller J, Rose-John S: HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood 2012;119: 5173-5181.
55. Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, Berenson JR: Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997;276: 1851-1854.
56. Guo Y, Xu F, Lu T, Duan Z, Zhang Z: Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012;38: 904-910.
57. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y: Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5: 1731-1740.
58. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qin X, van de Velde H, Xie H, Thomas SK: A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;161: 357-366.
59. Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, Patel N, Smith ES, Wang W, Prabhala R, Tai YT, Tassone P, Anderson KC, Munshi NC: A high-affinity fully human anti-IL-6 mab, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009;15: 7144-7152.
60. Sporeno E, Savino R, Ciapponi L, Paonessa G, Cabibbo A, Lahm A, Pulkki K, Sun RX, Toniatti C, Klein B, Ciliberto G: Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood 1996; 87: 4510-4519.
61. Honemann D, Chatterjee M, Savino R, Bommert K, Burger R, Gramatzki M, Dorken B, Bargou RC: The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. Int J Cancer 2001;93: 674-680.
62. Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC: Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin Cancer Res 2005;11: 4251-4258.
63. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S: Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268: 160-167.
64. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J: Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008;111: 1021-1028.
65. Guo DJ, Han JS, Li YS, Liu ZS, Lu SY, Ren HL: In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma. Oncol Lett 2012;4: 311-318.
66. Sansone P, Bromberg J: Targeting the interleukin- 6/Jak/Stat pathway in human malignancies. J Clin Oncol 2012;30: 1005-1014.
67. Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P, Podar K, Catley L, Hideshima T, Chauhan D, Caulder E, Neilan CL, Vaddi K, Li J, Gramatzki M, Fridman JS, Anderson KC: Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther 2009;8: 26-35.
68. Mascarenhas J, Hoffman R: Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 2012;18: 3008-3014.
69. Burger R, Gramatzki M: JAK kinases in leukemias, lymphomas, and multiple myeloma; in Fabbro D, McCormick F (eds): Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ, Humana Press, 2006, pp. 115-144.
70. Chari A, Pri-Chen H, Jagannath S: Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma. Clin Lymphoma Myeloma Leuk 2013;13: 333-337.